Rare skin disease biotech eyes $16 million IPO as trial results come in and cash runs out

Armed with the first clinical results on its lead drug, a repurposed Duchenne’s candidate with a controversial past, and virtually no money, Processa Pharmaceuticals $PCSA is looking to go public and raise $16 million.